HARMONICARE Receives FDA Approval for FGFR2/3 Inhibitor ABSK061 Clinical Trial in Pediatric Achondroplasia
核心洞察
HARMONICARE PHARMA (搜索) has received FDA approval for a clinical trial of ABSK061, a highly selective small molecule FGFR2/3 (搜索) inhibitor, for treating children with achondroplasia (搜索).
The drug is currently undergoing Phase II clinical trials for achondroplasia (搜索) treatment, with first subject dosing completed in China in December 2025.
Preclinical studies demonstrate that ABSK061 possesses strong target inhibition activity, favorable pharmacokinetic characteristics, and promising safety features.
HARMONICARE-B (搜索)'s subsidiary HARMONICARE PHARMA (搜索) has secured approval from the United States Food and Drug Administration for a new drug clinical trial application of its highly selective small molecule FGFR2/3 (搜索) inhibitor ABSK061 for the treatment of children with achondroplasia (搜索) (ACH). This regulatory milestone represents a significant advancement in addressing a rare genetic disorder affecting skeletal development in pediatric patients.
Clinical Development Progress
ABSK061 is currently undergoing a Phase II clinical trial for the treatment of achondroplasia (搜索), with the first subject dosing completed in China in December 2025. This progression demonstrates the company's commitment to advancing treatment options for children affected by this rare skeletal dysplasia.
Drug Profile and Mechanism
ABSK061 is independently developed by HARMONICARE PHARMA (搜索) as a highly active and selective small molecule FGFR2/3 (搜索) inhibitor. The fibroblast growth factor receptor (FGFR) pathway plays a crucial role in bone and cartilage development, making it a strategic therapeutic target for achondroplasia (搜索) treatment.
Preclinical Evidence
Preclinical studies have demonstrated that ABSK061 possesses strong target inhibition activity, favorable pharmacokinetic characteristics, and promising safety features. These findings provide the scientific foundation supporting the drug's advancement into clinical development and regulatory approval for human testing.
The FDA approval for clinical trials in the United States expands the geographical scope of ABSK061's development program, potentially accelerating patient access to this investigational therapy across multiple markets.